A decade of fragment-based drug design: strategic advances and lessons learned.
Since the early 1990s, several technological and scientific advances - such as combinatorial chemistry, high-throughput screening and the sequencing of the human genome - have been heralded as remedies to the problems facing the pharmaceutical industry. The use of these technologies in some form is now well established at most pharmaceutical companies; however, the return on investment in terms of marketed products has not met expectations. Fragment-based drug design is another tool for drug discovery that has emerged in the past decade. Here, we describe the development and evolution of fragment-based drug design, analyse the role that this approach can have in combination with other discovery technologies and highlight the impact that fragment-based methods have made in progressing new medicines into the clinic.
Hajduk
Philip J
PJ
Pharmaceutical Discovery Division, Abbott Laboratories, Abbott Park, Illinois 60064, USA. philip.hajduk@abbott.com
Greer
Jonathan
J
D003659:Decision Making, Organizational; D015195:Drug Design; D004345:Drug Industry / Q000458:organization & administration / Q000639:trends; D008024:Ligands; D015394:Molecular Structure; D013678:Technology, Pharmaceutical / Q000379:methods* / Q000639:trends; D013997:Time Factors
D008024:Ligands